Teri F. Willey has been hired by the Cold Spring Harbor Laboratory to help it commercialize some of its discoveries and turn them into products.
As vice president of business development and technology transfer, a new position at the lab, Willey will direct the lab's commercialization and technology transfer activities, including patenting, licensing, company start-ups, and corporate partnerships and collaborations.
She comes to the lab from Mount Sinai Medical Center, where she led the center's technology transfer and business development efforts.
CSHL has an extensive history of biomedical discovery and technology advancement and has sparked more than 20 start-up biotech companies, cancer drug developer OSI Pharmaceuticals, which was recently acquired by Astellas.
"CSHL's transformative discoveries over many years in such areas as cancer, autism and other neuropsychiatric disorders, genome analysis, plant biology, and biofuels have significant commercial applications that will improve diagnostic and therapeutic approaches in the clinic as well as in agriculture and energy production," said CSHL President Bruce Stillman.
"The appointment of Teri Willey to this new position will ensure that our research advances are applied to society's biggest challenges in healthcare, the environment, and world hunger and will enable us to maximize the economic potential of the biomedical research cluster on Long Island. Ms. Willey has an outstanding reputation and track record, and we are extremely pleased to welcome her to CSHL."
Before Mount Sinai, she was founding chief executive and executive director, Cambridge Enterprise Ltd, The University of Cambridge, and was a co-founder and Managing Partner of ARCH Development Partners.